ADC Market to Triple Growth By 2030 Driven By Big Pharma?
After two decades of trial and error in antibody drug-conjugate (ADC) development, the field is poised to deliver a broad range of targeted medicines to treat a variety of tumor types. These are a large emerging class of highly effective drugs that combine immunotherapy and chemotherapy. In ADCs, the most commonly targeted antigens are ERBB2, […]
ADC Market to Triple Growth By 2030 Driven By Big Pharma? Read More »